Kelsy Ketchum

After the federal government's investments into rapid and at-home testing, there are concerns whether manufacturers can meet demand.

The startup's algorithm combines biomarkers, patient demographics, and past medical histories to determine a patient's risk of severe sepsis.

Researchers in Thailand have developed a test using a sweat sample from the armpit to measure automatic compounds indicating SARS-CoV-2 infection.

The blood test detects the presence of seven proteins to determine if a patient is likely to respond to the FDA-approved treatment siltuximab.

The accelerator provides laboratory space, marketing and regulatory guidance, and supplies to firms looking to set up in the US.

From automated systems not recognizing their genders to denials of insurance claims, many obstacles hinder transgender patients from receiving necessary medical care. 

The technology has been licensed by MGeneRx, which plans to commercialize it in the US first, then expand to low- and middle-income countries.

The firm's Immunoblot tests use recombinant proteins to achieve high sensitivity with lower false positives and expands the number of species detected.

Although demand for the firm's COVID-19 testing declined in H1, other diagnostic areas and its international business have grown.

Specific will start its commercial activities in Europe starting in the fourth quarter of 2021 and plans to expand to the US next year.